---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-060140"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-12T23:48:40.865620+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma prices $1.75M registered direct offering of 500,000 shares/pre-funded warrants at $3.50/share

## Summary
- Gross proceeds of $1.75M from sale of 300,000 shares and 200,000 pre-funded warrants at $3.50/share.
- Single institutional investor; closing expected July 31, 2023.
- Net proceeds for R&D, working capital, and possible debt repayment.
- Wilmington Capital Securities acting as exclusive placement agent.
- Offering made under effective shelf registration statement (File No. 333-260588).

## SEC filing metadata
- accession: 0001213900-23-060140
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390023060140/0001213900-23-060140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390023060140/ea182424-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-060140
- JSON: https://secwatch.observer/filing/0001213900-23-060140.json
- Plain text: https://secwatch.observer/filing/0001213900-23-060140.txt

## Key facts
- Material Agreements
  ABVC BIOPHARMA, INC. entered into Securities Purchase Agreement with certain investors (the "Purchasers") valued at gross proceeds of $1,750,000 (effective 2023-07-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors (the "Purchasers")
  - Value: gross proceeds of $1,750,000
  - Effective: 2023-07-27
  source text: ABVC BioPharma, Inc. (the “ Company ”) and certain investors (the “ Purchasers ”) entered into that certain securities purchase agreement on July 27, 2023 (the “ Purchase Agreement ”) relating to the offer and sale of 300,000 shares of common stock (the “ Shares ”), par value $0.001 per share (the “ Common Stock ”) and 200,000 pre-funded warrants, at an exercise price of $0.01 per share (the “ Pre-funded Warrants ”), in a registered direct offering (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390023060140/0001213900-23-060140-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.